Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/531,900	SCHUTZE ET AL.	
Examiner	Art Unit	

The MAILING DATE of this communication appears on the o	over sheet with the correspondence address
THE REPLY FILED 29 September 2008 FAILS TO PLACE THIS APPLICAT	ION IN CONDITION FOR ALLOWANCE.
 The reply was filed after a final rejection, but prior to or on the same da application, applicant must timely file one of the following replies: (1) a application in condition for allowance; (2) a Notice of Appeal (with applied for Continued Examination (RCE) in compliance with 37 CFR 1.114. T 	n amendment, affidavit, or other evidence, which places the eal fee) in compliance with 37 CFR 41.31; or (3) a Request
periods:	
a) The period for reply expiresmonths from the mailing date of the firm	•
b) The period for reply expires on: (1) the mailing date of this Advisory Action no event, however, will the statutory period for reply expire later than SIX N Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHE	MONTHS from the mailing date of the final rejection.
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).	
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the phave been filed is the date for purposes of determining the period of extension and thounder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statuset forth in (b) above, if checked. Any reply received by the Office later than three may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	e corresponding amount of the fee. The appropriate extension fee atory period for reply originally set in the final Office action; or (2) as
2. ☑ The Notice of Appeal was filed on <u>29 September 2008</u> . A brief in com	aliance with 27 CEP 41 27 must be filed within two months of
the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension appeal. Since a Notice of Appeal has been filed, any reply must be file AMENDMENTS	sion thereof (37 CFR 41.37(e)), to avoid dismissal of the
	e date of filing a brief, will not be entered because
(a) They raise new issues that would require further consideration a	
(b) They raise the issue of new matter (see NOTE below);	,,
(c) They are not deemed to place the application in better form for a appeal; and/or	
(d) ☐ They present additional claims without canceling a correspondin	g number of finally rejected claims.
NOTE: See Continuation Sheet. (See 37 CFR 1.116 and 41.33	s(a)).
4. 🔲 The amendments are not in compliance with 37 CFR 1.121. See attac	hed Notice of Non-Compliant Amendment (PTOL-324).
5. Applicant's reply has overcome the following rejection(s):	
 Newly proposed or amended claim(s) would be allowable if sub_ non-allowable claim(s). 	
7. For purposes of appeal, the proposed amendment(s): a) will not be how the new or amended claims would be rejected is provided below of the status of the claim(s) is (or will be) as follows: Claim(s) allowed:	
Claim(s) objected to:	
Claim(s) rejected: <u>1 and 11-21</u> .	
Claim(s) withdrawn from consideration:	
AFFIDAVIT OR OTHER EVIDENCE	
 The affidavit or other evidence filed after a final action, but before or or because applicant failed to provide a showing of good and sufficient re was not earlier presented. See 37 CFR 1.116(e). 	
9. The affidavit or other evidence filed after the date of filing a Notice of A entered because the affidavit or other evidence failed to overcome all showing a good and sufficient reasons why it is necessary and was no	rejections under appeal and/or appellant fails to provide a
10. The affidavit or other evidence is entered. An explanation of the statu	
REQUEST FOR RECONSIDERATION/OTHER	of the dame and entry is below of attached.
11. The request for reconsideration has been considered but does NOT	place the application in condition for allowance because:
12. Note the attached Information <i>Disclosure Statement</i> (s). (PTO/SB/08) 13. Other:	Paper No(s)
October 13, 2008	W. O. O. : 17
	yllis G. Spivack/ ary Examiner, Art Unit 1614

Continuation of 3. NOTE: Independent claim 12 - under final rejection - was drawn to methods for the treatment of atypical and esophageal symptoms of gastroesophageal reflux, digestive bleeding and dyspepsia comprising administering a medicament comprising tenatoprazole, wherein dependent claims 17 and 18 limited the subject matter under consideration to treatment of atypical and esophageal symptoms of gastroesophageal reflux, digestive bleeding and dyspepsia as they occur during the pathological conditions of nocturnal esophageal reflux and Barrett's esophagus. Thus the originally presented invention had been constructively elected by original presentation for prosecution on the merits. The amendments presented in the Reply filed after FINAL under 37 CFR §1.116 require further search and consideration.

2